Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246348 | 0.91 | PARP1 (0.48) | ATMPARP1PARP2KMT2AMEN1 | |
| SCHEMBL1001867 | 0.87 | MEN1 (0.46) | PARP1PARP2ACHEKMT2AMEN1 | |
| SCHEMBL1002130 | 0.86 | PARP1 (0.50) | PARP1PARP2BCHEACHECCR3 | |
| SCHEMBL1003044 | 0.85 | PARP1 (0.53) | ATMPARP1PARP2BCHEACHE | |
| SCHEMBL1005063 | 0.81 | PARP1 (0.48) | PARP1PARP2BCHEACHECCR3 | |
| SCHEMBL1003204 | 0.81 | PARP1 (0.51) | PARP1PARP2BCHEACHEDRD2 | |
| SCHEMBL1001898 | 0.80 | PARP1 (0.49) | PARP1PARP2ACHEKMT2AMEN1 | |
| SCHEMBL1000989 | 0.80 | PARP1 (0.51) | PARP1PARP2ACHEDRD2DRD4 | |
| SCHEMBL1002269 | 0.78 | PARP1 (0.43) | PARP1PARP2BCHEACHE | |
| SCHEMBL27733521 | 0.78 | ATM (0.50) | ATMBCHEACHEKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | claimed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007021309-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | ATM 2847/4885PARP1 3651/4885PARP2 4209/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | ATM 2847/4885PARP1 3651/4885PARP2 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.